Girentuximab (cG250) is a chimeric monoclonal antibody that targets carbonic anhydrase IX (CAIX), which is a cell surface antigen expressed in various cancers, such as clear cell renal cell carcinoma (ccRCC), urothelial carcinoma, and TNBC. The gene discussed is CA9; the disease is nonpapillary renal cell carcinoma.